Coenzyme Q$_{10}$ partially restores pathological alterations in a macrophage model of Gaucher disease

Mario de la Mata$^{1,2}$, David Cotán$^{1,2}$, Manuel Oropesa-Ávila$^{1,2}$, Marina Villanueva-Paz$^{1,2}$, Isabel de Lavera$^{1,2}$, Mónica Álvarez-Córdoba$^{1,2}$, Raquel Luzón-Hidalgo$^{1,2}$, Juan M. Suárez-Rivero$^{1,2}$, Gustavo Tiscornia$^{3}$ and José A. Sánchez-Alcázar$^{1,2,*}$

Abstract

**Background:** Gaucher disease (GD) is caused by mutations in the GBA1 gene which encodes lysosomal β-glucocerebrosidase (GCase). In GD, partial or complete loss of GCase activity causes the accumulation of the glycolipids glucosylceramide (GlcCer) and glucosylsphingosine in the lysosomes of macrophages. In this manuscript, we investigated the effects of glycolipids accumulation on lysosomal and mitochondrial function, inflammasome activation and efferocytosis capacity in a THP-1 macrophage model of Gaucher disease. In addition, the beneficial effects of coenzyme Q$_{10}$ (CoQ) supplementation on cellular alterations were evaluated.

**Chemically-induced Gaucher macrophages** were developed by differentiating THP-1 monocytes to macrophages by treatment with phorbol 12-myristate 13-acetate (PMA) and then inhibiting intracellular GCase with conduritol B-epoxide (CBE), a specific irreversible inhibitor of GCase activity, and supplementing the medium with exogenous GlcCer. This cell model accumulated up to 16-fold more GlcCer compared with control THP-1 cells.

**Results:** Chemically-induced Gaucher macrophages showed impaired autophagy flux associated with mitochondrial dysfunction and increased oxidative stress, inflammasome activation and impaired efferocytosis. All abnormalities were partially restored by supplementation with CoQ.

**Conclusion:** These data suggest that targeting mitochondria function and oxidative stress by CoQ can ameliorate the pathological phenotype of Gaucher cells. Chemically-induced Gaucher macrophages provide cellular models that can be used to investigate disease pathogenesis and explore new therapeutics for GD.

**Keywords:** Gaucher disease, Coenzyme Q$_{10}$, Mitochondria, Oxidative stress, Inflammasome, Efferocytosis

Background

In LSDs, mutations in lysosomal hydrolases or transporters result in the accumulation of specific macromolecules, leading to progressive reduction in the capacity of the lysosome for normal degradation processes, which in turn leads to secondary changes such as impairment in autophagic flux, mitochondrial dysfunction and inflammation [1]. Gaucher disease (GD), the LSD with the highest prevalence, is caused by mutations in the GBA1 gene that results in defective and insufficient activity of the enzyme β-glucocerebrosidase (GCase). Decreased catalytic activity and/or instability of GCase leads to accumulation of glucosylceramide (GlcCer) and glucosylsphingosine in the lysosomes of macrophages. Three clinical forms (phenotypes) of the disease are commonly recognized (Types 1, 2 and 3) of which by far the most severe are those affecting the brain (Types 2 and 3). Current treatments for GD include enzyme replacement therapy with recombinant GCase and substrate-reduction therapy which decreases the biosynthesis of glucosylceramides and thereby reduces their accumulation [2]. Many studies have implicated mitochondrial...
dysfunction in the pathogenesis of lysosomal diseases in general and in GD in particular [3, 4]. The most pronounced effect occurs in macrophages that participate in ingesting blood cells and apoptotic lymphocytes. Thus, the primary cell type affected in GD is the lipid laden macrophage known as Gaucher cell. As macrophages normally degrade large amounts of cellular membrane lipids by phagocytosis, when GCase is absent or impaired, glycosphingolipids accumulate within the macrophage lysosome and the engorged cells in turn are deposited in the liver, spleen, and lung, causing organ enlargement and progressive dysfunction. GCase is distinguished from other O-glycosyl hydrolases by an acidic pH optimum and a preference for glycolipids. Little is known about the mechanisms by which GlcCer accumulation leads to disease phenotype, particularly for those in which severe neuropathology occurs. Specifically, it is not known if altered macrophage function is responsible for all of the pathological manifestations in all affected tissues, or whether secondary biochemical changes caused directly by GlcCer accumulation in the specific tissues also play a role in the pathological process. Therefore, determining how GlcCer accumulation perturbs the function of lysosomes and other organelles can be important in elucidating the cascade of events that give rise to the pathological consequences in GD.

In order to mimic the pathological phenotype of the disease, an in vitro cellular model of Gaucher disease was developed by treating the THP-1, a human monocytic cell line differentiated into macrophage, with a specific inhibitor of GCase, conduritol beta epoxide (CBE) [5] and the concomitant supplementation with exogenous GlcCer (chemically-induced Gaucher THP-1 macrophages). Autophagy flux, mitochondrial dysfunction, inflammasome activation and efferocytosis capacity were examined in chemically-induced Gaucher THP-1 macrophages. In addition, as mitochondrial dysfunction and/or impaired mitochondria elimination may be associated with alterations of lysosome-dependent processes, treatment with coenzyme Q10 (CoQ), an antioxidant and mitochondrial energizer, was evaluated for the improvement of cellular pathological alterations.

Methods
Reagents
Monoclonal Anti-Actin and Anti-NLRP3 antibodies were obtained from Sigma-Aldrich (St. Louis, MO). Mitosox Red, Mitotracker Red CMXRos, CMH2-DCFDA, 10-N-nonyl acridine orange (NAO), LysoSensor Green DND-189, tetramethylrhodamine methyl ester (TMRM), CellTracker™ Green and Hoechst 33342 were from Invitrogen/Molecular Probes (Eugene, OR). Anti-GCase was obtained from Abcam. Anti-cytochrome c antibody was obtained from BD Biosciences Pharmingen (San Jose, CA) and anti-GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) monoclonal antibody (clone 6 C5) was from Calbiochem-Merck Chemicals Ltd. (Nottingham, UK). CBE, Anti-MAP LC3 (N-20), anti-LAMP-1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Protease inhibitors were from Boehringer Mannheim (Indianapolis, IN). Anti-IL-1β were obtained (Bioss, Inc). Anti-Caspase 1 was obtained from (Cell Signaling Technology, CST). The anti-GlCer rabbit anti-serum was purchased from Glycobiotech GmbH (Kükelshoven, Germany). Glucoscerosides from Gaucher’s spleen (GlcCer) was obtained from Matreya LLC (Pleasant Gap, PA, USA). The Immun Star HRP substrate kit was from Bio-Rad Laboratories Inc. (Hercules, CA, USA). All other chemicals were purchased from Sigma-Aldrich.

Chemically-induced Gaucher macrophages
THP-1 cells (human monocytic cell line) were cultured in RPMI medium supplemented with penicillin, streptomycin, and 10% fetal bovine serum at 37 °C in a humidified 5% CO₂ atmosphere and were first differentiated into macrophages by phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) incubation at a final concentration of 100 ng/mL for 3 d and it was followed by 1 d in PMA-free medium before treatments. Then, the Gaucher disease phenotype was induced by chemical inhibition of acid β-glucosidase with 2,5 mM CBE [5]. To exacerbate Gaucher phenotype, the culture medium of THP-1 macrophages was supplemented with exogenous GlcCer (200 μM).

Immunofluorescence microscopy
Immunofluorescence microscopy was performed using standard methods as previously described [6]. Cover slips were analyzed using a fluorescence microscope (Leica DMRE, Leica Microsystems GmbH, Wetzlar, Germany). Deconvolution studies and 3-dimensional projections were performed using a DeltaVision system (Applied Precision, Issaquah, WA) with an Olympus IX-71 microscope.

Measurement of mitochondrial reactive oxygen species (ROS) production
Mitochondrial ROS generation was assessed using the mitochondrial superoxide indicator MitoSOX Red, according to the manufacturer’s instructions. ROS levels were expressed relative to mitochondrial mass (ROS signal/NAO signal) determined by flow cytometry. Cells were stained with 10 μM NAO for 10 min at 37 °C in the dark.

Measurement of intracellular H₂O₂ content
H₂O₂ levels were measured using non fluorescent CMH₂-DCFDA (5-[and-6]-chloromethyl-2',7'-dichlorodihydrofluoresceindiacetate, acetyl ester), which diffuses across membranes and is oxidized to fluorescent
dichlorofluorescein (DCF). Cultured cells were incubated with CMH2DCFDA diluted in medium at 5 μM for 30 min at 37 °C. After that, cells were analyzed by flow cytometry.

**Determination of mitochondrial membrane potential (ΔΨm)**

ΔΨm was measured by staining with 20 nM TMRM or 100 nM Mitotracker Red CMXRos (30 min incubation). Cells were subsequently analyzed by fluorescence microscopy and flow cytometry.

**Immunoblotting analysis**

Western blotting was performed using a standard protocol [7] and the Immun Star HRP detection kit (Bio-Rad Laboratories Inc., Hercules, CA, USA).

**Lysosome acidification**

Lysosome acidification was measured by staining with 5 μM LysoSensor Green DND-189. LysoSensor was added to cells in growth medium and incubated at 37 °C for 30 min before imaging and flow cytometry analysis. Lysosome acidification was also measured by 10 μg/ml acridine orange staining (15 min incubation at 37 °C). Typically, 10–15 fluorescence microscopy images were collected from 3 separate experiments and the red/green ratio of discrete puncta (n = 200) were calculated using Image J.

**Phagocytosis assay**

Apoptosis was induced by treatment with 10 μM CPT for 48 h treatment in CellTracker-labelled H460 cells adhered to glass coverslips. Apoptosis was assessed by fluorescence microscopy observing nuclei fragmentation by Hoechst staining, cytochrome c release, and caspase 3 activation. Then, apoptotic cells were co-incubated with control or chemically-induced Gaucher macrophages (150,000 cells/well). After 8 h of co-incubation at 37 °C, cells were fixed in 3.8% paraformaldehyde. The number of control and chemically-induced Gaucher macrophages interacting and engulfing cell fragments was calculated in ten random fields in triplicate by fluorescence microscopy.

**IL-1β levels**

Samples from culture media from control and chemically-induced Gaucher macrophages were collected and stored at −80 °C until the assay. IL-1β levels in culture media were determined in triplicates by commercial ELISA kits (Human IL-1β CytoSetTM, Invitrogen, Camarillo, CA, USA).

**Statistical analysis**

All results are expressed as mean ± SD of 3 independent experiments. The measurements were statistically analyzed using the Student’s t test for comparing 2 groups and analysis of variance for more than 2 groups. The level of significance was set at p < 0.05.

**Results**

**Establishing a chemically-induced Gaucher macrophage model**

First, we examined whether chemically-induced Gaucher THP-1 macrophages reproduce the pathological phenotype of this disease. As shown in Fig. 1a and b, GlcCer accumulated in macrophages treated with CBE for 72 h. This accumulation was significantly increased by exogenous 200 μM GlcCer supplementation (Fig. 1a and b). GlcCer accumulation mainly colocalized with lysosomes which were labeled with LAMP-1 (Fig. 1a and b). Hematoxylin/eosin staining of chemically-induced Gaucher THP-1 macrophages also showed cells with dilated vesicles presumably representing GlcCer accumulation in lysosomes (Fig. 1c). These alterations were particularly evident in cells treated with CBE and supplemented with GlcCer.

As GlcCer accumulation was significantly higher in THP-1 cells treated with CBE and supplemented with GlcCer we decided to work with this model in successive experiments. Appropriate controls showing that pathophysiological alterations are also more pronounced with the combined treatment are provided in (Additional files 1: Figures S1–S8).

**CoQ treatment partially ameliorates GlcCer accumulation in chemically-induced Gaucher THP-1 macrophages**

As mitochondrial dysfunction has been associated with alterations of lysosome-dependent processes, treatment with CoQ, an antioxidant and mitochondrial energizer, was evaluated for improving glycolipids accumulation in cells treat with CBE and supplemented with GlcCer. Supplementation with CoQ (25 μM) of chemically-induced Gaucher THP-1 macrophages partially reduced GlcCer accumulation and the number of GlcCer/LAMP-1 puncta (Fig. 2a and b). Furthermore, in concordance with this, there was a drastically reduction of dilated vesicles in hematoxylin/eosin stainings (Fig. 2c).

**Autophagic flux is impaired in chemically-induced Gaucher THP-1 macrophage model**

As GlcCer accumulation in lysosomes may interfere with lysosomal function and impair lysosomal fusion with autophagosomes, we next examined autophagosome maturation. To ascertain whether or not autophagic flux was impaired in chemically-induced Gaucher THP-1 macrophages, we checked the levels of LC3-II in the presence of bafilomycin A1 (Baf), a specific inhibitor of vacuolar H +-ATPases and a blocker of autophagosome-lysosome fusion (Fig. 3a and b). As expected, Baf treatment in control THP-1 macrophages led to a significant increase in the
amount of LC3-II suggesting that autophagic flux was normal. However, basal LC3-II levels were increased in chemically-induced Gaucher THP-1 macrophages, suggesting autophagosome accumulation. Furthermore, Baf treatment had no effect in LC3-II levels indicating that autophagic flux was impaired (Fig. 3a and b). Supplementa-

Effect of CoQ supplementation on lysosomal pH and mitochondrial membrane potential (ΔΨm) in chemically-induced Gaucher THP-1 macrophages

Little is known about how GlcCer accumulation in lysosomes leads to cellular pathology. One critical question
is whether GlcCer mediates all of its pathological effects from within the lysosome, or whether some GlcCer interact with biochemical and cellular pathways located in other organelles as mitochondria.

As in Gaucher’s disease the accumulation of GlcCer has been associated with an elevation in lysosomal pH [8], we first determined whether GlcCer accumulation in chemically-induced Gaucher THP-1 macrophages affects
lyosomal pH. Results indicated that the accumulation of GlcCer impaired the acidification of these vesicles (Fig. 4a). Flow cytometry analysis confirmed that LysoSensor Green DND-189 fluorescence was decreased in chemically-induced Gaucher THP-1 macrophages (Fig. 4b). In addition, to assess mitochondrial dysfunction in chemically-induced Gaucher THP-1 macrophages, ΔΨm was evaluated by TMRM staining and fluorescence microscopy visualization. TMRM fluorescence was decreased in chemically-induced Gaucher THP-1 macrophages, which reflects mitochondrial depolarization (Fig. 4a). Mitochondrial depolarization was also confirmed by flow cytometry analysis (Fig. 4c).

To elucidate whether CoQ had a beneficial effect on lysosomal pH and ΔΨm impairment, chemically-induced Gaucher macrophages were treated with 25 μM CoQ for 72 h. CoQ treatment resulted in a significant improvement of both lysosomal pH and ΔΨm (Fig. 4a, b and c).

Lysosome acidification impairment in chemically-induced Gaucher macrophages was also confirmed by acridine orange staining. Chemically-induced Gaucher macrophages showed a decrease in the red/green ratio after acridine orange staining consistent with decreased lysosomal acidity (Fig. 5a and b). Supplementation with CoQ (25 μM) significantly increased the red/green ratio.

**Effect of CoQ on reactive oxygen species (ROS) production in chemically-induced Gaucher macrophages**

It is well established that mitochondrial dysfunction is associated with increased ROS production [9]. Therefore, we examined mitochondrial ROS and H2O2 levels in chemically-induced Gaucher macrophages. Mitochondrial superoxide production and H2O2 levels were increased approximately by 2.5-fold and by 2-fold respectively (Fig. 6a and b), suggesting increased oxidative stress in chemically-induced Gaucher macrophages. Supplementation with CoQ (25 μM), induced a notably reduction in mitochondrial superoxide and H2O2 levels in chemically-induced Gaucher macrophages, but had no effect in control cultures (Fig. 6a and b).
Effect of CoQ on mitophagy in chemically-induced Gaucher macrophages

Mitochondria can be degraded through mitophagy. To determine whether the accumulated autophagosomes in chemically-induced Gaucher macrophages contained mitochondria, we performed immunofluorescence double staining with antibodies against LC3 (autophagosome marker) and cytochrome c (mitochondrial marker) (Fig. 7a). LC3 staining was markedly increased in chemically-induced Gaucher THP-1 macrophages respect to control macrophages. In addition, LC3 signal strongly colocalized with cytochrome c, suggesting that mitochondria are engulfed by autophagosomes in chemically-induced Gaucher THP-1 macrophages. Supplementation with CoQ (25 μM) partially reduced the number of LC3/cytochrome c puncta (Fig. 7b).

Effect of CoQ on inflammasome activation in chemically-induced Gaucher macrophages

To determine the effect of GlcCer accumulation on inflammasome activation, we evaluated NLRP3 expression levels and caspase-1 activation in chemically-induced Gaucher macrophages. We found increased NLRP3 expression levels and caspase-1 cleavage as well as...
as enhanced levels of intracellular and secreted IL-1β compared to controls (Fig. 8a, b and c). CoQ treatment resulted in a significant decrease in NLRP3 expression levels, caspase-1 cleavage and intracellular and secreted IL-1β levels (Fig. 8a, b and c).

Defective efferocytosis in chemically-induced Gaucher macrophages

Given that apoptotic cells are rapidly phagocytosed by macrophages, a process that represents a critical step in tissue remodeling, immune responses, and the resolution...
of inflammation, we evaluated the phagocytosis capacity of chemically-induced Gaucher macrophages. In vitro phagocytosis assays indicate a defective efferocytosis by chemically-induced Gaucher macrophages with a significant decrease of contacts and engulfment of apoptotic cells. CoQ treatment resulted in a significant increase of efferocytosis capacity in chemically-induced Gaucher macrophages (Fig. 9a, b and c).

Discussion

Our study shows that GCase deficient activity and accumulation of GlcCer in a macrophage model of GD can cause lysosomal and mitochondrial dysfunction associated with inflammasome activation and impaired efferocytosis. This study also showed that it is possible to ameliorate the cellular pathological consequences of GlcCer accumulation by targeting mitochondria and oxidative stress with CoQ treatment.

In order to mimic the disease state, an in vitro model of Gaucher disease was developed by treating THP-1 macrophages with a specific irreversible inhibitor of GCase, CBE, and exogenous GlcCer supplementation. In previous works, GCase deficiency has been mimicked treating he human neuroblastoma SHSY-5Y cell line with CBE [10]. The treatment with CBE resulted in fragmentation of mitochondria, significant progressive
decline in mitochondrial membrane potential, reduction of ATP synthesis and an increase in ROS production. Furthermore, an animal model and in vitro models for Gaucher disease have been produced by injecting mice or treating macrophages with CBE, causing intracellular storage of endogenous GlcCer [11, 12]. However, in addition to endogenously synthesized GlcCer, storage material in Gaucher cells is also thought to originate from the turnover of exogenously derived lipids in cell membranes of phagocytosed red and white blood cells. For this reason and in order to exacerbate the disease phenotype, in addition to GCase inhibition, we supplemented the culture medium with exogenous GlcCer. In our cell model, lipid storage would be expected to occur

Fig. 7 Colocalization of autophagosome and mitochondria markers in chemically-induced Gaucher macrophages. a Mitochondria Image analysis of LC3 and cytochrome c immunostaining in control and chemically-induced Gaucher macrophages. Control and chemically-induced Gaucher macrophages were cultured in the presence or absence of CoQ (25 μM) for 72 h. Cells were fixed and immunostained with anti-LC3 (autophagosome marker) and cytochrome c (mitochondrial marker) and examined by fluorescence microscopy. b Quantification of LC3/cytochrome c puncta in control and chemically-induced Gaucher macrophages incubated with or without CoQ (n = 100 cells). Data represent the mean ± SD of three separate experiments. *p < 0.05 between control and chemically-induced Gaucher macrophages. *p < 0.05 between the presence and the absence of CoQ treatment.
much more rapidly and to more closely mimic the disease state. These GlcCer-laden Gaucher macrophages have a characteristic morphology with extensive presence of lysosomal lipid deposits. Currently, many of the available mouse models of Gaucher disease are not suitable for these studies because most knock-in mouse models carrying human mutations in glucocerebrosidase do not display an accurate disease phenotype or are lethal [13]. Thus, cell-based Gaucher disease models may provide an alternative approach for evaluating the efficacy of new therapeutic strategies.

In GD, accumulation of sphingolipids has been shown to alter autophagy by reducing autophagosome clearance, and so promoting their accumulation [14]. Indeed, alteration of autophagic flux has been demonstrated in GD cell models [3]. Furthermore, increased number of autophagosomes has been observed in hypomorphic prosaposin mice carrying the homozygous V394L Gba1 mutation that showed accumulation of GlcCer [15]. Degradation of engulfed material is primarily mediated by lysosomal enzymes that function optimally within a narrow range of acidic pH values. Elevation of lysosomal pH in Gaucher cells interferes with the degradation process and may contribute to the associated pathologies [16]. Recently, there have been increased reports showing that lysosomal pH may be regulated [17] and that GlcCer accumulation may have an important role in its dysregulation [8]. Our results showed that GlcCer accumulation impaired lysosome acidification and as a result may alter the activity of lysosomal hydrolases which may result in secondary substrate accumulation [18]. The accumulation of primary and secondary substrates provokes a cascade of events that impacts not only the endosomal–autophagic–lysosomal system, but also in other organelles including mitochondria, the ER, Golgi, peroxisomes, and overall the cell function [1].

Furthermore, our results confirm previous experiments that showed that autophagic flux is reduced in most LSDs [19]. This is evident from the combined elevation of autophagic substrates and autophagosome-associated LC3-II in chemically-induced Gaucher macrophages.

Constitutive macroautophagy maintains mitochondrial quality by selectively degrading dysfunctional mitochondria via a process known as mitophagy [20]. Therefore, reduced autophagic flux in LSDs may lead to the persistence of dysfunctional mitochondria [21–25]. In addition of impaired mitochondria quality control, some authors have hypothesized that variations in GlcCer and ceramide might play an important role in the development of mitochondrial dysfunction in GD [26]. Furthermore, it has been reported that the sphingolipid ceramides provoke oxidative stress by disrupting mitochondria and inducing lethal mitophagy [27]. In agreement with these results, we have previously reported that GlcCer is accumulated mainly in the lysosomal and mitochondrial compartments in fibroblasts derived from Gaucher patients and that both accumulation of GlcCer and
impairment of autophagic flux may induce mitochondrial dysfunction in Gaucher disease [3].

Dysfunctional mitochondria are involved in the pathogenesis of several neurodegenerative diseases. The proper elimination of damaged mitochondria is needed in postmitotic neurons because progressive accumulation of damaged mitochondria might eventually lead to cell death. Mitochondrial dysfunction with reduced respiratory chain complex activities, increased ROS production and decreased potential in neurons and astrocytes has recently been reported in a mouse model of type II neuronopathic GD [28].

GlcCer accumulation within inflammatory cells as macrophages may contribute to persistent and altered inflammatory responses in GD. In GD patients, elevated levels of some cytokines and chemokines have been reported including IL-1β, interleukin-1 receptor antagonist, IL-6, IL-8, IL-10, IL18, TNF-α, M-CSF, and pulmonary and activation-regulated chemokine (PARC or CCL-18) [29–32]. A similar finding was noted using THP-1 cells differentiated into macrophages by retinoic acid and treated with the GCase inhibitor CBE [33]. Normal human mesenchymal stromal cells treated with CBE also showed an up-regulation of genes involved in proteolysis, lipid homeostasis, and the inflammatory response [34]. In this manuscript, we show that impaired autophagic flux is associated with inflammasome activation and increased maturation of IL-1β in a chemically-
induced Gaucher macrophage model. These findings provide a link between impaired autophagy and increased secretion of pro-inflammatory cytokines in Gaucher cells. Consistent with our results, macrophages derived from peripheral monocytes from patients with type 1 Gaucher disease with genotype N370S/N370S showed an increased secretion of interleukins IL-1β and IL-6 [35]. Our findings are also supported by studies in patients with type 1 GD [29], in mouse models of GD [36] and in iPSC-derived cells [37].

However the exact mechanism by which GlcCer accumulation activates the NLPR3 inflammasome is not yet understood. Several recent data have shown that autophagy, and in particular mitophagy, are key links among inflammasome, ROS production and mitochondrial dysfunctions [38, 39].

Macrophages are involved in many essential processes including the removal of pathogens and dead cells through phagocytosis [40]. This may contribute to the accumulation of unphagocytosed debris from cells undergoing apoptosis in the course of homeostatic tissue remodeling and repair. Mutant GBA macrophages accumulate undigested lysosomal material, which disrupts endocytic recycling and impairs their migration and engulfment of dying cells. This causes a buildup of unengulfed cell debris.

Given that chemically-induced Gaucher macrophages manifest their defective storage phenotype, we also evaluated their phagocytosis capability. We found impaired efferocytosis in chemically-induced Gaucher macrophages. In agreement with our findings, impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher Disease has been previously reported [41].

Given that defects in energy metabolism and oxidative stress have been demonstrated to play a role in the pathogenesis of GD, we envisioned that the treatment with coenzyme CoQ could also exert beneficial therapeutic effects. The fundamental role of CoQ in mitochondrial bioenergetics and its well-acknowledged antioxidant properties constitute the basis for its clinical use in several mitochondrial disorders [47, 48]. Consistent with these findings, the treatment with CoQ improved mitochondrial/lysosomal function, increased autophagic flux and reduced inflammasome activation as well as improved efferocytosis capacity of chemically-induced Gaucher macrophages.

These results, however, should be interpreted with caution since the positive effects of CoQ in vitro may not have an equivalent beneficial effect when translated to human clinical trials as it has been recently demonstrated in two large trials in Parkinson and Huntington diseases [47, 48].

Conclusion
Our results support the hypothesis that lysosomal dysfunction interferes with the clearance of damaged mitochondria and that the two critical pathways, lysosomal and mitochondrial dysfunction converge in the pathogenesis of GD. In addition, CoQ supplementation partially corrected many of the cellular pathophysiological alterations. Therefore, we proposed that boosting lysosomal function in conjunction with improvements of mitochondrial function will have a protective effect on GD. Studies in a suitable animal model may provide preclinical data, which may support clinical trials with CoQ given in human patients with GD.

Additional file

Additional file 1: Supplementary data. (PDF 2022 kb)

Abbreviations
AO: Acridine orange; BAF: Bafilomycin A1; BBB: Blood brain barrier; CBE: Conduritol B-epoxide; CMH2-DCFDA: (5-(and-6)-chloromethyl-2,7'-dichlorodihydrofluoresceindiacetate, acetyl ester); CNS: Central nervous system; CoQ: Coenzyme Q 10; ER: Endoplasmic reticulum; ERAD: ER associated degradation system; ERT: Enzyme replacement therapy; GCase: β-glucocerebrosidase; GD: Gaucher disease; GlcCer: Glucosylceramide; GlcSph: Glucosyolphosphosine; IgGs: Immunoglobulins G; LPS: Lipopolysaccharide; LSDs: Lysosomal storage diseases; PD: Parkinson’s disease; PMA: Phorbol 12-myristate 13-acetate; ROS: Reactive oxygen species; SRT: Small-molecule substrate reduction therapy; ΔΨm: mitochondrial membrane potential

Acknowledgements
Our acknowledgement to the Microscopy Core of the CABD.

Funding
This work was supported by FIS PI13/00129 grant, Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER-Unión Europea), Proyecto de Investigación de Excelencia de la Junta de Andalucía CTS-5725, and by AEPMI (Asociación de Enfermos de Patología Mitochondrial) and ENACH (Asociación de Enfermos de Neurodegeneración con Acumulación Cerebral de Hierro).

Availability of data and materials
All relevant data are included in supplementary materials.
Authors’ contributions
MdIM, GT and DC have made contribution in the acquisition, analysis and interpretation of the data and drafted the manuscript. MdIM, MOA, MVP, IDL, MAC, RLH, JMSP were involved in doing the experiments. JASA is the academic supervisor and involved in the supervision of the study. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1Centro Andaluz de Biología del Desarrollo (CABD), Consejo Superior de Investigaciones Científicas, Universidad Pablo de Olavide, Carretera de Utrera Km 1, Sevilla 41013, Spain. 2Centro de Investigación Biomédica en Red: Enfermedades Raras, Instituto de Salud Carlos III, Madrid 28029, Spain. 3Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.

Received: 11 November 2016 Accepted: 20 January 2017
Published online: 06 February 2017

References
1. Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723–34.
2. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci. 2004;25(3):147–51.
3. de la Mata M, Cotan D, Oropesa-Avila M, Garrido-Maraver J, Cordero MD, Villanueva Paz M, Delgado Pavon A, Alcocer-Gomez E, de Lavera I, Yobt-Gonzalez P, et al. Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant beta-Glucocerebrosidase Activity and Mitochondrial Function in Neuronalopathic Forms of Gaucher Disease. Sci Rep. 2015;5:10903.
4. Gegge ME, Schapika AH. Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol Dis. 2016;90:43–50.
5. Hein KE, Mekle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab. 2007;92(4):336–45.
6. Cotan D, Cordero MD, Garrido-Maraver J, Oropesa-Avila M, Rodriguez-Hernandez A, Gomez Izquierdo L, De la Mata M, De Miguel M, Lorite JB, Infante ER, et al. Secondary coenzyme Q10 deficiency triggers mitochondrial degradation by mitophagy in MELAS fibroblasts. FASEB J. 2011;25(8):2669–87.
7. Rodriguez-Hernandez A, Cordero MD, Salvati L, Artuch R, Pineda M, Briones P, Gomez Izquierdo L, Cotan D, Navas P, Sanchez-Alcazar JA. Coenzyme Q10 deficiency triggers mitochondrial degradation by mitophagy. Autophagy. 2009;5(1):19–32.
8. Silence DJ. Glucosylceramide modulates endosomal pH in Gaucher disease. Mol Genet Metab. 2013;109(2):194–200.
9. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 2014;94(3):909–50.
10. Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, Wood NW, Hardy J, Mark Cooper J, Schapira AH. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int. 2013;62(1):1–7.
11. Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, et al. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain alpha-Synuclein Aggregation, Microgliia and Complement C1q Activation in Mice. Antioxid Redox Signal. 2015;23(6):550–64.
12. Vardi A, Zigdon I, Meshcherikova A, Klein AD, Yaacobi C, Elam R, Kenwood BM, Rahim AA, Massaro G, Merrill Jr AH, et al. Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. J Pathol. 2016;239(4):496–509.
13. Farfel-Becker T, Vtnhr EB, Futerman AH. Animal models for Gaucher disease research. Dis Model Mech. 2011;4(6):746–52.
14. Tamboli IV, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM, Saftig P, Sandhoff K, Walter J. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J Neurosci. 2011;31(5):1837–49.
15. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kittanani K, Hannun YA, Witte DP, Xu YH, et al. Neuronopathic Gaucher disease in the mouse viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010;19(6):1088–97.
16. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001; 19(5):591–8.
17. Butor C, Griffiths G, Aronson JR, NV, Varki A. Co-localization of hydrolytic enzymes with widely disparate pH optima: implications for the regulation of lysosomal pH. J Cell Sci. 1995;108(Pt 6):2123–9.
18. Walkley SJ, Vanier MT. Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta. 2009;1794(4):726–36.
19. Raben N, Shea L, Hill V, Plotz P. Monitoring autophagy in lysosomal storage disorders. Methods Enzymol. 2009;452:47–9.
20. Kim I, Rodriguez-Sanchez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys. 2007;462(2):245–53.
21. Ezaki J, Wolfe LS, Komimani E. Specific delay in the degradation of mitochondrial ATP synthase subunit c in late infantile neuronal ceroid lipofuscinosis is derived from cellular proteolytic dysfunction rather than structural alteration of subunit c. J Neurochem. 1996;67(4):1677–87.
22. Jennings Jr JJ, Zhu JH, Rabbiy I, Luo X, Chu CT, Kiseleiev K. Mitochondrial aberrations in mucolipidosis Type IV. J Biol Chem. 2006;281(51):39041–50.
23. Settembre C, Fraldi A, Rubinstein DC, Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008;4(1):113–4.
24. Takamura A, Higaki K, Kajimaki K, Otsuka S, Ninomiya H, Matsuoka O, Ohno K, Suzuki Y, Namba E. Enhanced autophagy and mitochondrial aberrations in mutant G(M1)-gangliosidosis. Biochem Biophys Res Commun. 2008;367(3): 616–22.
25. Tessitore A, Pirozi M, Auricchio A. Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. PathoGenetics. 2009;2(1):4.
26. Strasberg P. Cerebrosides and psychosine disrupt mitochondrial functions. Biochim Biophys Acta. 1986;864(5):485–9.
27. Sentelle RD, Senkal CE, Jiang W, Fonnesamy S, Genser C, Selvar SP, Ramesh VK, Peterson YK, Lemasters JJ, Szulc ZM, et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol. 2012;8(10):831–8.
28. Oselbrane LD, Rahim AA, Hargreaves IP, Gegge ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, Duchen MR. Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson’s disease. Cell Metab. 2013;17(6):941–53.
29. Allen MJ, Byer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. OJM. 1997;90(1):19–25.
30. Balreira A, Cavallari M, Sa Miranda MC, Arosa FA. Uncoupling between CD1d and iNKT cells reveals an altered inflammatory secretome. Blood. 2009;114(15):3181–9.
31. Liu J, Halene S, Yang M, Iqbal J, Yang R, Mehal WZ, Chuang WL, Jain D, Yuen T, Sun L, et al. Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci U S A. 2012;109(23):10018–23.
32. Michelakakis H, Spanou C, Kondyl E, Dimiriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta. 1996;1317(3):219–26.
33. Balreira A, Cavallari M, Sa Miranda MC, Arosa FA. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness. Immunobiology. 2010;215(6):505–13.
34. Campeau PM, Rafie M, Boivin MN, Sun Y, Grabowski GA, Galipeau J. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009;114(15):3181–90.
35. Afkali E, Moaven N, Borgor DK, Lopez G, Westbroek W, Chae JJ, Maragan J, Patnaik S, Maniwang E, Gonzalez AN, et al. Lysosomal storage and impaired autophagy lead to inflammation activation in Gaucher macrophages. Aging Cell. 2015;14(1):77–88.
36. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, Werth N, Sandhoff R, Sandhoff K, Proia RL. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucocerebrosidase accumulation. J Clin Invest. 2002;109(9):1215–21.
37. Panicker LM, Miller D, Awad O, Boxe V, Lun Y, Park TS, Zambidis ET, Sgambato JA, Feldman RA. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells. 2014;32(9):2338–49.
38. Pollet-Perez L, Despouy G, Delage-Mourroux R, Boyer-Guitaut M. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol. 2015;4:184–92.
39. Venditti P, Di Stefano L, Di Meo S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion. 2013;13(2):71–82.
40. Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33:643–75.
41. Marodi L, Kaposzta R, Toth J, Laszlo A. Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Blood. 1995;86(12):4645–9.
42. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Vega AF, de la Mata M, Pavon AD, Alcocer-Gomez E, Calero CP, Paz MV, Alanis M, et al. Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed). 2014;19:619–33.
43. Artuch R, Arciil A, Mas A, Mones E, Vilaseca MA, Pineda M. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics. 2004;35(2):95–8.
44. Ebadi M, Govitrapong P, Sharma S, Muralikrishnan D, Shavali S, Pellett L, Schafer R, Albano C, Eken J. Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of Parkinson's disease. Biol Signals Recept. 2001;10(3–4):224–53.
45. Matallonga L, Arias A, Coll MJ, Garcia-Villoria J, Gort L, Ribes A. Treatment effect of coenzyme Q10 and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. J Inherit Metab Dis. 2014;37(3):439–46.
46. Gille L, Nohl H. The existence of a lysosomal redox chain and the role of ubiquinone. Arch Biochem Biophys. 2000;375(2):347–54.
47. McCarr T, McDermott M, Kieburz K, de Blicke EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88(2):152–59.
48. Parkinson Study Group QEI, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WH, Haas R, Juncos JL, Nutt JG, Voss TS, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543–52.